FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 890 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Study Finds the Cost of Treating Metastatic Breast Cancer Could More... August 3, 2021 What to Know About Coping With Breast Cancer During Pregnancy: An... November 14, 2023 Study Finds Disparities in Access to Opioids for Cancer Pain at... February 14, 2023 Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from... October 24, 2019 Load more HOT NEWS FDA Approval Likely to Change Initial Treatment for Some People with... Similarity of Molecular Portraits in Synchronous Bilateral Breast Cancers Could be... Celebrating 75 years of NHS cancer care Record Impact Factor for Annals of Oncology Highlights Growing Influence of...
